Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden

Scandinavian Journal of Urology and Nephrology

Volumn 46, Issue 1, 2012, Pages 48-53

  Alhadad, Alaa ^a   Sterner, Gunnar ^a   Svensson, Ke ^a   Alhadad, Hussein ^b   Leander, Peter ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Gadolinium based contrast media; Nephrogenic systemic fibrosis; Renal failur

Indexed keywords

GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOXETIC ACID;

ADULT; ARTICLE; BODY WEIGHT; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SWEDEN;

AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; GADOLINIUM; GLOMERULAR FILTRATION RATE; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; RENAL DIALYSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SWEDEN;

EID: 84856185793     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2011.621142     Document Type: Article

References (51)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1.
2. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007;2:264-7.
3. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006;16: 2619-21.
4. Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M, et al. Cardiac and vascular metal deposition and high mortality in nephrogenic systemic fibrosis. Kidney Int 2008;73:1413-18.
5. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139:903-6.
6. Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant 2011;26:1099-101.
7. Khurana A, Nickel AE, Greene JF Jr, Narayanan M, High WA, Foulks CJ. Successful pregnancy in a hemodialysis patient and marked resolution of her nephrogenic systemic fibrosis. Am J Kidney Dis 2008;51:e29-32.
8. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-8.
9. Marckmann P. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. Eur J Radiol 2008; 66:18-790.
10. Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, et al. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008;51: 966-75.
11. Becker S, Walter S, Witzke O, Wilde B, Hillen U, Napieralski D, et al. The German registry for nephrogenic systemic fibrosis: findings from 23 patients. Clin Nephrol 2010;73:426-30.
12. Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 2010;256:735-43.
13. AuntMinnie.com, FDA panel. NSF incidence falls with gadolinium restrictions. Wayne Forrest, AuntMinnie.com staff writer, December 9, 2009.
14. Zou Z, Ma L, Li H. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital. J Magn Reson Imaging 2009;30:1309-12.
15. Abujudeh HH, Rolls H, Kaewlai R, Agarwal S, Gebreananya ZA, Saini S, et al. Retrospective assessment of the prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging 2009;30:1335-40.
16. Chrysochou C, Power A, Shurrab AE, Hussain S, Moser S, Lay J, et al. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol 2010;5:484-9.
17. Janus N, Launay-Vacher V, Karie S, Clement O, Ledneva E,Frances C, et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol 2010;73:35-79.
18. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54.
19. Nyman U, Grubb A, Sterner G, Björk J. The CKD-EPI and MDRD equations to estimate GFR. Validation in the Swedish Lund-Malmö Study cohort. Scand J Clin Lab Invest 2011;71:129-38.
20. Levey AS, Coresh J. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39 (2 Suppl 1):1-266.
21. Darsow U, Wollenberg A, Simon D, Taeb A, Werfel T, Oranje A, et al. European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV Eczema Task Force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010;24: 317-28.
22. Ghauri AS, Nyamekye IK. Leg ulceration: the importance of treating the underlying pathophysiology. Phlebology 2010;25 (Suppl 1):42-51.
23. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 1983;249:1743-5.
24. Morcos SK, Thomsen HS. Nephrogenic systemic fibrosis: more questions and some answers. Nephron Clin Pract 2008; 110:c24-31.
25. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in renal failure patients exposed to gadodiamide, a gadolinium (Gd)-containing magnetic resonance contrast agent. Invest Radiol 2008;43: 141-4.
26. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22:3174-8.
27. Panda S, Bandyopadhyay D, Tarafder A. Nephrogenic fibrosing dermopathy: a series in a non-Western population. J Am Acad Dermatol 2006;54:155-9.
28. Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, Su LD, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 2008;190:736-41.
29. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007; 22:3179-85.
30. Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 2007;26: 1198-203.
31. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett RW, Djamali A, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243: 148-57.
32. Thomsen HS, Marckmann P. Extracellular Gd-CA: differences in prevalence of NSF. Eur J Radiol 2008;66:180-3.
33. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2007; 2:200-2.
34. Peak AS, Sheller A. Risk factors for developing gadolinium- induced nephrogenic systemic fibrosis. Ann Pharmacother 2007;41:1481-5.
35. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007;7:2425-32.
36. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis. Arthritis Rheum 2007;56: 3433-41.
37. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadoliniumbased MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007;242:64-79.
38. Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245:168-75.
39. Perazella MA. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf 2008;3:6-775.
40. Idee JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008;248:7-78.
41. Khurana A, Greene JF Jr, High WA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol 2008;59:218-24.
42. Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008;248:807-16.
43. Romanelli P, Bouzari N. New clinical syndromes in dermatology. Semin Cutan Med Surg 2006;25:79-86.
44. Swaminathan S, Arbiser JL, Hiatt KM, High W, Abdul-Ezz S, Horn TD, et al. Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase. J Am Acad Dermatol 2010;62:343-5.
45. Bucala R. Circulating fibrocytes: cellular basis for NSF. J Am Coll Radiol 2008;5:36-9.
46. Varani J, DaSilva M, Warner RL, Deming MO, Barron AG, Johnson KJ, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 2009;44:74-81.
47. Lemy AA, del Marmol V, Kolivaras A, High WA, Laporte M, Nortier JL. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience. J Am Acad Dermatol 2010;63:389-99.
48. Jain R, Levine M. Correction to the relative risk calculation for gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis. Radiology 2010;255:30-78.
49. Leiner T, Kucharczyk W. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada and Europe. J Magn Reson Imaging 2009;30:1357-63.
50. European Society of Uroradiology (ESUR). Guidelines for contrast media, version 7. www.esur.org.
51. Perriss R, Løkkegaard H, Løgager V, Chabanova E, Thomsen HS. Preliminary experience with contrast-enhanced MR angiography in patients with end-stage renal failure. Acad Radiol 2005;12:652-7